|
|
 |
SENSEX
|
 |
-444.39
|
-0.62%
|
71581.76
|
|
|
NIFTY
|
 |
-148.60
|
-0.68%
|
21562.20
|
|
|
Nasdaq
|
 |
13.77
|
0.09%
|
14524.07
|
|
|
Nikkei 225
|
 |
89.13
|
0.27%
|
33377.42
|
|
|
FTSE 100
|
 |
-33.50
|
-0.43%
|
7689.60
|
|
|
 |
|
|
|
|
|
YOU ARE ON
Equity
|
|
|
|
|
|
|
|
|
05-01-2024
|
|
|
Aurobindo Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 |
|
|
|
05-01-2024
|
|
|
Aurobindo Pharma Limited has informed the Exchange about Loss of Share Certificates |
|
|
|
05-01-2024
|
|
|
AUROBINDO PHARMA LIMITED has informed the Exchange about Loss of share certificates |
|
|
|
04-01-2024
|
|
|
Aurobindo Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 |
|
|
|
28-12-2023
|
|
|
Aurobindo Pharma Limited has informed the Exchange regarding a press release dated December 27, 2023, titled "Eugia Pharma receives USFDA Approval for Posaconazole Injection, 300 mg/16.7 mL (18 mg/mL), Single-Dose Vial". |
|
|
|
28-12-2023
|
|
|
Aurobindo Pharma Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results. |
|
|
|
27-12-2023
|
|
|
Aurobindo Pharma Limited has informed the Exchange regarding a press release dated December 27, 2023, titled "Eugia Pharma receives USFDA Approval for Posaconazole Injection, 300 mg/16.7 mL (18 mg/mL), Single-Dose Vial". |
|
|
|
27-12-2023
|
|
|
Aurobindo Pharma Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results. |
|
|
|
26-12-2023
|
|
|
Aurobindo Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 |
|
|
|
26-12-2023
|
|
|
AUROBINDO PHARMA LIMITED has informed the Exchange about Closure of Trading Window |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|